Sensars Neuroprosthetics
- hard tech
- horizon europe
- eit ecosystem
- consumer electronics
- neurology
- drones
- eit health
- direct-to-consumer
- seal of excellence ec
- headstart (eit health)
- neuroscience
- orthopedic
- european health catapult (eit health)
- investor network (eit health)
- mentoring and coaching network (eit health)
- prosthetics
- mentoring and coaching network 2020 (eit health)
- headstart 2018 (eit health)
- investor network 2018 (eit health)
- neuro stimulation
- european health catapult 2018 (eit health)
Financials
Estimates*
EUR | 2015 | 2016 | 2017 | 2018 |
---|---|---|---|---|
Revenues | <1m | <1m | <1m | <1m |
% growth | - | 1 % | (8 %) | 4 % |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
N/A | Grant | ||
N/A | Grant | ||
$100k | Seed | ||
€50.0k | Grant | ||
€100k | Grant | ||
N/A | Grant | ||
N/A | Grant | ||
€398k | Grant | ||
€50.0k | Grant | ||
$1.6m | Grant | ||
€1.5k | Grant | ||
* | CHF20.0k | Grant | |
* | N/A | Seed | |
* | €1.1m | Grant | |
Total Funding | AUD5.5m |
Recent News about Sensars Neuroprosthetics
EditSensArs Neuroprosthetics is a pioneering startup specializing in the development of neuroprosthetic systems. The company operates within the medical technology market, specifically focusing on the creation of bionic prosthetics for individuals who have experienced limb loss. SensArs' innovative technology stimulates the peripheral nervous system to restore sensory feedback, thereby eliminating pain caused by nerve damage.
The company's primary revenue stream comes from the sale of its breakthrough neuroprosthetic systems. These systems have undergone successful human clinical trials and have been recognized by the FDA as a Breakthrough Device. This designation is given to devices that have the potential to provide more effective treatment or diagnosis for life-threatening or debilitating diseases.
SensArs has been successful in securing substantial funding for its research and development activities. Most notably, it has received a €3 million grant from the European Union’s Horizon Research and Innovation program. The company plans to use these funds to further develop and test its product.
The startup serves a global market of patients suffering from chronic pain due to nerve damage. It has established partnerships with prestigious institutions, clinics, and accelerators worldwide, which have helped it gain recognition and credibility in the medical technology industry.
SensArs' future plans include exploring new possibilities in neurotechnology, such as brain-computer interfaces, prosthetic control, and treatments for obesity and depression.
Keywords: Neuroprosthetics, Bionic Prosthetics, Medical Technology, Peripheral Nervous System, Sensory Feedback, Pain Elimination, FDA Breakthrough Device, Research and Development, Chronic Pain Treatment, Neurotechnology.